Market
Which geographic region will see the first large-scale deployment of Moderna's H5N1 vaccine by the end of 2026?
2
Resolution / Starting Odds
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
Official announcements from Moderna or government agencies
Story
U.S. Awards Moderna $590 Million for H5N1 Bird Flu Vaccine mRNA-1018 Development
Jan 17, 2025, 10:07 PM
The U.S. Department of Health and Human Services (HHS) has awarded Moderna Inc. $590 million to advance the development of a vaccine against bird flu, specifically targeting the H5N1 strain. This funding is in addition to the $176 million HHS provided last year for the late-stage development and testing of a pre-pandemic mRNA-based vaccine against H5N1 avian influenza. The investment aims to accelerate the development of Moderna's mRNA-1018 vaccine, which is currently in a Phase 1/2 study to assess its safety and immunogenicity in healthy adults and is planned for Phase 3 trials in 2025. The Biden-Harris Administration has emphasized the importance of this initiative, citing the unpredictability and danger of avian flu variants, including H5 and H7, to humans. This move is part of a broader effort by the administration, which also includes a $306 million investment to enhance disease surveillance, laboratory testing, and monitoring of the H5N1 avian flu's impact.
View original story
Similar markets
Distributed in North America, Europe, and Asia • 25%
Distributed in North America and Europe • 25%
Distributed in North America only • 25%
Global distribution • 25%
United States • 25%
Other • 25%
United Kingdom • 25%
European Union • 25%
Northeast • 25%
West • 25%
South • 25%
Midwest • 25%
Government clinics • 25%
Pharmacies • 25%
Private hospitals • 25%
Community centers • 25%
Moderna • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Europe • 25%
Asia • 25%
North America • 25%
Other • 25%
India • 25%
Other • 25%
United States • 25%
European Union • 25%
More than 100 million doses • 25%
10 to 50 million doses • 25%
Less than 10 million doses • 25%
50 to 100 million doses • 25%
Not Completed • 25%
Unsuccessful • 25%
Partially Successful • 25%
Successful • 25%
Unsuccessful • 25%
Trial ongoing • 25%
Successful without FDA approval • 25%
Successful with FDA approval • 25%
Other • 25%
Southeast Asia • 25%
Europe • 25%
North America • 25%
Other • 25%
United Kingdom • 25%
United States • 25%
Canada • 25%